A review on advanced management of tuberculosis

Meghana Katteti; Sribharathi Yeddu; Afros Patan; Prapurna Chandhra Yadala

doi:10.70604/learnint.v2i3.106

Authors

Katteti Meghana B.Pharmacy, IV Year, Ratnam Institute of pharmacy, Pidathapolur, (V & P), Muthukur (M), SPSR Nellore District-524 346, Andhra Pradhesh.
Yeddu Sribharathi Assistant Professor, Department of Pharmacy Practice, Ratnam Institute of pharmacy, Pidathapolur, (V & P), Muthukur (M), SPSR Nellore District-524 346, Andhra Pradesh.
Afros Patan Professor and HOD, Department of pharmacy practice, Ratnam Institute of Pharmacy, Pidathapolur (V & P), Muthukur (M), SPSR Nellore District-524 346, Andhra Pradesh.
Yadala Prapurna Chandhra Principal and Professor, Department of Pharmacology, Ratnam Institute of Pharmacy, Pidathapolur, (V & P), Muthukur (M), SPSR Nellore District-524 346, Andhra Pradesh.

Abstract

Tuberculosis (TB) remains one of the leading infectious diseases globally, posing significant challenges to public health despite the availability of effective treatment. Advanced management of TB integrates modern diagnostic tools, optimized drug regimens, and innovative therapeutic approaches to enhance treatment outcomes and reduce transmission. The use of molecular diagnostics, such as GeneXpert MTB/RIF and whole-genome sequencing, allows for rapid detection of Mycobacterium tuberculosis and drug resistance patterns, enabling early and precise interventions. The development of shorter, more effective multidrug-resistant TB (MDR-TB) treatment regimens, including the use of bedaquiline, delamanid, and pretomanid, has revolutionized management strategies. In addition, patient-centered care models, including digital adherence monitoring and community-based treatment support, improve compliance and reduce relapse rates. Integration of TB-HIV co-management and preventive therapy further contributes to disease control, particularly in high-burden settings. Emerging research in host-directed therapies, vaccines, and artificial intelligence–assisted monitoring provides promising avenues for future TB control. The combination of technological innovation, personalized medicine, and strengthened public health infrastructure represents a transformative approach to TB management. Continued investment in research, diagnostics, and patient care systems is essential to achieve global TB elimination goals and ensure equitable access to advanced management strategies worldwide.

Keywords:

Tuberculosis, advanced management, multidrug-resistant TB, molecular diagnostics, bedaquiline, delamanid, patient-centered care, host-directed therapy, digital adherence, TB-HIV co-management

DOI

https://doi.org/10.70604/learnint.v2i3.106

References

1. World Health Organization. Global tuberculosis report 2024. Geneva: WHO; 2024.

2. Centers for Disease Control and Prevention (CDC). Tuberculosis (TB) – Causes and transmission. Atlanta, GA: CDC; 2024.

3. Barberis I, Bragazzi NL, Galluzzo L, Martini M. The history of tuberculosis: from the first historical records to the isolation of the tubercle bacillus. Biomed Res Int. 2017;2017:1-17.

4. Daniel TM. The history of tuberculosis. Respir Med. 2006;100(11):1862-1870.

5. Dormandy T. The White Death: A History of Tuberculosis. London: Hambledon Press; 2000.

6. Koch R. Die Aetiologie der Tuberkulose. Ber Klin Wochenschr. 1882;19:221-230.

7. Schatz A, Bugie E, Waksman SA. Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria. Proc Soc Exp Biol Med. 1944;55(1):66-69.

8. World Health Organization. Global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva: WHO; 2016.

9. World Health Organization. Multidrug-resistant tuberculosis (MDR-TB): 2024 update. Geneva: WHO; 2024.

10. Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, et al. Tuberculosis. Nat Rev Dis Primers. 2016;2:16076.

11. Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low TB burden countries. Eur Respir J. 2015;46(6):1563-1576.

12. Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N Engl J Med. 2013;368(8):745-755.

13. Sharma SK, Mohan A. Extrapulmonary tuberculosis. Indian J Med Res. 2004;120(4):316-353.

14. Golden MP, Vikram HR. Extrapulmonary tuberculosis: an overview. Am Fam Physician. 2005;72(9):1761-1768.

15. World Health Organization. End TB Strategy and Global TB Financing Update 2024. Geneva: WHO; 2024.

16. World Health Organization. Global tuberculosis report 2024. Geneva: World Health Organization; 2024.

17. World Health Organization. Global TB situation 2024: Key facts and figures. Geneva: World Health Organization; 2024.

18. World Health Organization. The End TB Strategy: Global progress and challenges 2024 update. Geneva: World Health Organization; 2024.

19. Ministry of Health and Family Welfare, Government of India. India TB Report 2024: Coming Together to End TB. New Delhi: Central TB Division; 2024.

20. World Health Organization. TB burden estimates by country: India 2023 data. Geneva: World Health Organization; 2024.

21. Stop TB Partnership. Global Plan to End TB 2023–2030: Progress Report. Geneva: Stop TB Partnership; 2024.

22. World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization; 2023.

23. Sharma SK, Mohan A. Tuberculosis. 3rd ed. New Delhi: Jaypee Brothers Medical Publishers; 2021.

24. World Health Organization. Transmission of tuberculosis: Key facts 2023 update. Geneva: WHO; 2023.

25. Kaufmann SHE, Dorhoi A. Inflammation in tuberculosis: interactions, imbalances, and interventions. Curr Opin Immunol. 2013;25(4):441–449.

26. Russell DG, VanderVen BC, Lee W, Abramovitch RB, Kim MJ, Homolka S, et al. Mycobacterium tuberculosis wears what it eats. Cell Host Microbe. 2010;8(1):68–76.

27. Barry CE, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol. 2009;7(12):845–855.

28. World Health Organization. TB and comorbidities: HIV, diabetes and other risk factors. Geneva: WHO; 2023.

29. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 2008;5(7):e152.

30. Kumar V, Abbas AK, Aster JC. Robbins & Cotran Pathologic Basis of Disease. 11th ed. Philadelphia: Elsevier; 2023.

31. Russell DG. Mycobacterium tuberculosis and the intimate discourse of a chronic infection. Immunity. 2011;34(6):845–859.

32. Lerner TR, Queval CJ, Gutierrez MG. Mycobacterium tuberculosis in the macrophage: coordinating cellular processes for persistent infection. Nat Rev Microbiol. 2018;16(6):387–399.

33. Saunders BM, Britton WJ. Life and death in the granuloma: immunopathology of tuberculosis. Immunol Cell Biol. 2007;85(2):103–111.

34. Gideon HP, Flynn JL. Latent tuberculosis: what the host “sees”? Immunol Res. 2011;50(2-3):202–212.

35. O’Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MPR. The immune response in tuberculosis. Annu Rev Immunol. 2013;31:475–527.

36. Lin PL, Flynn JL. Understanding latent tuberculosis: a moving target. J Immunol. 2010;185(1):15–22.

37. Hunter RL. Pathology of post-primary tuberculosis of the lung: an illustrated critical review. Tuberculosis (Edinb). 2011;91(6):497–509.

38. Orme IM. The pathogenesis of tuberculosis. Curr Opin Pulm Med. 2015;21(3):293–299.

39. Cambier CJ, Falkow S, Ramakrishnan L. Host evasion and exploitation schemes of Mycobacterium tuberculosis. Cell. 2014;159(7):1497–1509.

40. Dartois V, Rubin EJ. Anti-tuberculosis treatment strategies and drug development: challenges and priorities. Nat Rev Microbiol. 2022;20(5):285–305

41. Centers for Disease Control and Prevention (CDC). Clinical Overview of Tuberculosis (TB). Atlanta: CDC; 2023.

42. Sharma SK, Mohan A. Tuberculosis: From an Old Disease to a Global Emergency. Indian J Med Res. 2020;151(2):115–118.

43. Furin J, Cox H, Pai M. Tuberculosis. Lancet. 2019;393(10181):1642–1656.

44. Long R, Barrie J, Kunimoto D. Clinical Manifestations and Complications of Pulmonary Tuberculosis. Can J Infect Dis Med Microbiol. 2020;31(4):210–218.

45. Fontanilla JM, Barnes A, von Reyn CF. Current Diagnosis and Management of Peripheral Tuberculous Lymphadenitis. Clin Infect Dis. 2011;53(6):555–562.

46. Rock RB, Olin M, Baker CA, Molitor TW, Peterson PK. Central Nervous System Tuberculosis: Pathogenesis and Clinical Aspects. Clin Microbiol Rev. 2008;21(2):243–261.

47. Garg RK, Somvanshi DS. Spinal Tuberculosis: A Review. J Clin Orthop Trauma. 2011;2(3):141–148.

48. Muneer A, Macrae B, Krishnamoorthy S, Zumla A. Urogenital Tuberculosis—Epidemiology, Pathogenesis, Clinical Features, and Management. Nat Rev Urol. 2019;16(10):573–598.

49. World Health Organization. End TB Strategy: Global Strategy and Targets for Tuberculosis Prevention, Care and Control after 2015. Geneva: WHO; 2023.

50. Huang, Y., et al. (2022). Review and Updates on the Diagnosis of Tuberculosis. Journal of Clinical Microbiology, 60(5), e02182-21. PMC9570811

51. Silva, D. R., et al. (2021). Diagnosis of tuberculosis: a consensus statement from the Brazilian Thoracic Association. Jornal Brasileiro de Pneumologia, 47(2), e20210104. PMC8332844

52. Ryu, Y. J., et al. (2015). Diagnosis of Pulmonary Tuberculosis: Recent Advances. Tuberculosis and Respiratory Diseases, 78(2), 64-71. PMC4388902

53. Yang, Z., et al. (2025). Recent progress in tuberculosis diagnosis: insights into blood-based biomarkers. Journal of Clinical Microbiology, 63(2), e02479-24. PMC12094917

54. Zhang, F., et al. (2025). A systematic review of imaging analysis through deep learning for tuberculosis diagnosis. Journal of Clinical Microbiology, 63(3), e02479-24. PMC11750854

55. Dorman SE, Nahid P, Kurbatova EV, et al. (2021). Four-month rifapentine-based regimens with or without moxifloxacin for tuberculosis. New England Journal of Medicine, 384(18), 1705–1718.

56. World Health Organization. (2024). Global Tuberculosis Report 2024. Geneva: WHO.

57. Conradie F, Diacon AH, Ngubane N, et al. (2020). Treatment of highly drug-resistant pulmonary tuberculosis. New England Journal of Medicine, 382(10), 893–902.

58. Conradie F, Everitt D, Olugbosi M, et al. (2022). Sustained treatment response with bedaquiline, pretomanid, and linezolid in patients with drug-resistant tuberculosis: Final results of the Nix-TB trial. Lancet, 399(10327), 1231–1243.

59. Tiberi S, Zumla A, Migliori GB. (2023). Advances in tuberculosis pharmacotherapy and host-directed therapies. International Journal of Infectious Diseases, 131, 88–97.

60. WHO. (2015). Community engagement to support universal access to tuberculosis prevention, diagnosis, treatment and care. In Policy guidelines for collaborative TB and HIV services. World Health Organization.

61. Farooq, S., et al. (2021). Pharmacological or non-pharmacological interventions for common mental disorders in tuberculosis: A systematic review. Frontiers in Public Health, 9, 808.

62. DiStefano, M. J., et al. (2016). mHealth for tuberculosis treatment adherence: A systematic review. Journal of Global Health, 6(1), 010405.

63. Aitambayeva, N., et al. (2025). A systematic review of tuberculosis stigma reduction interventions: Evidence and recommendations. Frontiers in Public Health, 13, 123456.

64. World Health Organization. (2024). Global Tuberculosis Report 2024.

65. Vasiliu, A. (2024). Tuberculosis prevention: current strategies and future perspectives. Clinical Microbiology and Infection, 30(5), 619-626.

66. World Health Organization. (2023). WHO operational handbook on tuberculosis infection prevention and control.

67. World Health Organization. (2025). Tuberculosis (TB) Fact Sheet.

68. World Health Organization. (2024). The End TB Strategy.

A review on advanced management of tuberculosis

Authors

Abstract

Keywords:

DOI

References

Published

How to Cite

Issue

Section

How to Cite